Table 2.
bFGF (4 ng/mL) | bFGF (4 ng/mL)+2i | hLIF (1000 U/mL)+2i | bFGF (8 ng/mL)+hLIF (1000 U/mL) | bFGF+hLIF | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transposase | PB | SB | PB | SB | PB | SB | PB | SB | —– | —– | —– | ||||||||
Transposon type | 3F | 4F | 6F | 4F | 3F | 4F | 6F | 4F | 3F | 4F | 6F | 4F | 3F | 4F | 6F | 4F | 3F | 4F | 6F |
No. of replicates | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 |
Colony formation rate (%) | 0.006 | 0.005 | 0.014 | 0.003 | 0.003 | 0.010 | 0.021 | 0.012 | 0.003 | 0.018 | 0.006 | 0.009 | 0.005 | 0.012 | 0.024 | 0.011 | 0 | 0 | 0 |
No. of colonies picked | 14 | 16 | 19 | 12 | 15 | 19 | 20 | 16 | 11 | 16 | 10 | 18 | 18 | 14 | 21 | 17 | 0 | 0 | 0 |
No. of opaque/nonproliferating colonies found | 42 | 37 | 28 | 54 | 51 | 48 | 33 | 36 | 28 | 47 | 39 | 34 | 56 | 52 | 46 | 57 | 54 | 26 | 40 |
Stable iPSC line/maximal passage | 0 | 0 | 1/P12a | 0 | 0 | 0 | 1/P18a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/P40b | 0 | 0 | 0 | 0 |
AP expression | — | — | No | — | — | — | Yes | — | — | — | Yes | — | — | — | Yes | — | — | — | — |
Pluripotency gene expression (RT-PCR) | — | — | No | — | — | — | No | — | — | — | No | — | — | — | Yes | — | — | — | — |
Teratoma formation | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 4/6 | NA | NA | NA | NA |
Cells ceased proliferation.
Culture with ongoing proliferation.
bFGF, basic fibroblast growth factor; hLIF, human leukemia inhibitory factor; PB, piggyBac transposon system; SB, Sleeping Beauty transposon system; iPSC, induced pluripotent stem cell; AP, alkaline phosphatase; NA, not assessed.